Platelet products are in short supply nowadays,while preparation of whole-blood platelets(WBPs) is shrinking year by year. It was generally recognized that apheresis platelets( Aps) have been superior to WBPs in many aspects. After universal leukoreduction for whole-blood,however, not only the efficacy but also the risks of transfusion-related adverse events,including bacterial contamination,virus spreading,alloimmunization,transfusion-associated acute lung injury,are nearly the same. Hence,WBPs should be picked up in absence of new evidence.